Journal
CLINICAL CANCER RESEARCH
Volume 24, Issue 9, Pages 2029-2031Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-17-3440
Keywords
-
Categories
Funding
- Fru Berta Kamprad Foundation
- National Health Services (Region Skane/ALF)
- Swedish Breast Cancer Group
- National Society of Breast Cancer Associations in Sweden (BRO)
Ask authors/readers for more resources
Breast and gynecologic cancers harboring PIK3CA mutations showed no significant responses to AZD5363, a pan-AKT catalytic inhibitor, in contrast with previous in vitro data showing activity of the drug in this subset of cancers. These results raise the question of how to select the most accurate predictive biomarkers of response. (C) 2018 AACR.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
